Profile

Cover photo
50 followers|24,317 views
AboutPostsPhotosVideos

Stream

Given Imaging

Shared publicly  - 
 
Celebrating the presidential proclamation that March is Colorectal Cancer Awareness Month!
1
Add a comment...

Given Imaging

Shared publicly  - 
 
Check out the @CNNI'Make,Create,Innovate' special on #PillCam http://bit.ly/ZNqeDW Risks http://qr2.it/Go/1933545
1
Add a comment...

Given Imaging

Shared publicly  - 
 
We’re proud to be #UnitedWithPurpose in raising over $16k for @CCFA and #crohns awareness
1
Add a comment...

Given Imaging

Shared publicly  - 
 
Thanks to all of our team members who participated in the #GivenScrubRun #crohnsawareness #UnitedWithPurpose 
1
Add a comment...

Given Imaging

Shared publicly  - 
 
Given Imaging Ends Exploration of Possible Sale Transaction  http://goo.gl/oQcex
1
Add a comment...
Have them in circles
50 people
Carlos Arias's profile photo
ANKITH.G. LALANAVAR's profile photo
Galuh Mahesa's profile photo

Given Imaging

Shared publicly  - 
 
News Release
Covidien Completes Acquisition of Given Imaging
DUBLIN, Ireland- (Business Wire) - Feb. 27th, 2014 -
Covidien plc (NYSE: COV) today announced that it has closed its acquisition of Given Imaging Ltd., providing the company additional scale and scope to serve a significant medical specialty, the multibillion dollar global gastrointestinal (GI) market.

PillCam SB is the most widely used, patient-friendly tool for directly visualizing the small bowel t ... 
PillCam SB is the most widely used, patient-friendly tool for directly visualizing the small bowel to detect and monitor abnormalities. This procedure is the standard of care for small bowel evaluation, helping healthcare practitioners detect the presence of lesions and what may be the source of obscure GI bleeding, Crohn’s disease and iron deficiency anemia. (Photo: Business Wire)

Under terms of the merger agreement, Covidien has acquired all outstanding Given shares for $30 per share or an aggregate consideration of approximately $860 million, net of cash and short-term investments acquired.

“Acquiring Given Imaging significantly expands Covidien’s GI Solutions business and supports the company’s strategy to comprehensively address key global specialties and procedures,” said Bryan Hanson, group president, Medical Devices & U.S., Covidien. “We are committed to providing clinicians with more accurate and efficient diagnostic technologies to help achieve better outcomes for patients.”

With this acquisition, Covidien now has one of the broadest portfolios for visualizing, monitoring and detecting abnormalities in the digestive system. A key technology in the Given portfolio is the worldwide market leading product PillCam®, a minimally-invasive, swallowed optical endoscopy technology for the small bowel, esophagus and colon that does not require sedation of the patient.

Financial Highlights

Covidien will report the Given Imaging business within the Advanced Surgical revenue reporting line. Given Imaging is expected to add between $40 and $50 million per quarter in incremental revenue.

On a reported U.S. GAAP basis, the transaction is expected to be dilutive to earnings per share (EPS) in fiscal 2014. On an adjusted basis, excluding one-time items and transaction costs, management expects the transaction to be neutral to EPS in fiscal 2014. The transaction is expected to be accretive to EPS both on a U.S. GAAP and on an adjusted basis in fiscal 2015 and beyond.

While the company has not completed its initial purchase price allocation and the final amount could differ significantly, it estimates incremental intangible asset amortization from the transaction to be approximately $35 to $45 million on an annual basis.

From a “cash earnings” standpoint, which excludes the impact of amortization, the transaction is expected to be accretive immediately.

Covidien management is not changing any of its guidance as a result of this transaction.

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. Please visit www.covidien.com to learn more about our business.

Forward-Looking Statements

Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, the ability to successfully integrate Given’s operations with Covidien’s and the time and resources required to do so; our ability to effectively introduce and market new products, keep pace with advances in technology and compete effectively; implementation of healthcare reform in the United States and globally; cost-containment efforts of customers, purchasing groups, third-party payors and governmental organizations; rising commodity costs; risk of cyber-attacks; intellectual property rights disputes; complex and costly regulation, including healthcare fraud and abuse regulations and the Foreign Corrupt Practices Act; recalls or safety alerts and negative publicity relating to Covidien or its products; product liability losses and other litigation liability; manufacturing or supply chain problems or disruptions; divestitures of some of our businesses or product lines; our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses; risks associated with doing business outside of the United States; foreign currency exchange rates; environmental liabilities; and tax legislation and potential tax liabilities. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the fiscal year ended September 27, 2013, and in subsequent filings with the SEC. We disclaim any obligation to update these forward-looking statements other than as required by law.



Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140227005589/en/

Source: Covidien plc

Covidien plc
Peter Lucht, 508-452-4168
Vice President, External Communications
peter.lucht@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President, Investor Relations
cole.lannum@covidien.com
or
Marguerite Copel, 203-821-4720
Vice President, Communications
marguerite.copel@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director, Investor Relations
todd.carpenter@covidien.com
1
Add a comment...

Given Imaging

Shared publicly  - 
 
We are honored to have been a part of the @FightCRC NASDAQ ceremony for #CRCAwarenessMonth #1MilStrong
1
Add a comment...

Given Imaging

Shared publicly  - 
 
@FightCRC and @GivenImaging are partnering to get behind a cure! Join One Million Strong and take the online pledge http://www.crcmillionstrong.org
1
Add a comment...

Given Imaging

Shared publicly  - 
 
Given Imaging Given Imaging Announces New Reimbursement Code for Its SmartPill Wireless Motility Capsule Procedure http://phx.corporate-ir.net/phoenix.zhtml?c=130061&p=irol-newsArticle_Print&ID=1775491&highlight=
1
Add a comment...

Given Imaging

Shared publicly  - 
 
The @CCFA#EscapeTheStall campaign to raise awareness for IBD in 2013 is really creative & inspiring. Check it out: http://bit.ly/13btIUb
1
Add a comment...
People
Have them in circles
50 people
Carlos Arias's profile photo
ANKITH.G. LALANAVAR's profile photo
Galuh Mahesa's profile photo
Contact Information
Contact info
Phone
1+ 972-4-909-7777
Email
Fax
1+ 972-4-959-2466
Address
Hermon Building New Industrial Park Yoqneam, Israel 20692
Story
Tagline
Expanding the Scope of GI (*Indications & Risks Information contained)
Introduction
Given Imaging is a world leader in GI medical devices, offering the broadest portfolio of capsule solutions to visualize the gastrointestinal tract and, through its Sierra Scientific subsidiary, specialty GI diagnostic solutions and high-resolution manometry.
Given Imaging pioneered capsule endoscopy, which is now the gold standard for small bowel visualization, and is supported by more than 1,200 peer-reviewed publications. The PillCam Platform is the recognized leader in this field and more than one million patients worldwide have benefited from PillCam capsule endoscopy.
In 2008, Given Imaging added the Bravo pH Monitoring System to its line of GI diagnostic tools. Bravo is the only wireless (catheter-free) ambulatory pH test to help clinicians manage gastroesophageal reflux disease (GERD). In April, 2010, Given Imaging acquired privately-held Sierra Scientific Instruments, the world leader in high-resolution manometry products and acid reflux monitoring solutions, including pH and impedance monitoring.
Today Given Imaging continues to innovate and offer cutting-edge solutions to its customers.

Management
Given Imaging is led by an international management team with extensive experience in endoscopy, medical technologies and imaging, drawn from global marketing and operations, regulatory affairs and finance.

Locations
The Company's corporate headquarters, research and development laboratories, and manufacturing facilities, are located in Yoqneam, Israel. With offices around the world, the Company's North American headquarters are located in Duluth, GA with European headquarters in Hamburg, Germany. Additional sales and marketing offices for Given Imaging are located in France, Japan, Australia, and Singapore, and a production facility is located in Ireland. Given Imaging's wholly-owned subsidiary, Sierra Scientific Instruments, is located in Los Angeles, CA, with manufacturing operations in Vietnam. Given Imaging's technology is currently marketed in more than 60 countries.



Risk Information
Fair balance statements/Risk information:


• To be used on all materials in the U.S. that contain product or procedure benefits

PillCam capsule endoscopy risk information (without PillCam COLON)

The risks of PillCam® capsule endoscopy include capsule retention, aspiration and skin irritation. After ingesting the PillCam capsule and until it is excreted, patients should not be near any source of powerful electromagnetic fields, such as one created by an MRI device. Endoscopic placement may present additional risks. Medical, endoscopic or surgical intervention may be necessary to address these complications, should they occur. Please consult the product user manual or refer to givenimaging.com for detailed information.



PillCam capsule endoscopy risk information (with PillCam COLON)

The risks of PillCam capsule endoscopy include capsule retention, aspiration and skin
irritation. Endoscopic placement may present additional risks. The risks associated with colon preparation include allergies or other known contraindications to any preparation agents or medications used for the PillCam COLON regimen, according to laxative medication labeling and per physician discretion. After ingesting the PillCam capsule and until it is excreted, patients should not be near any source of powerful electromagnetic fields, such as one created by an MRI device. Medical, endoscopic or surgical intervention may be necessary to address these complications, should they occur. A normal or negative capsule endoscopy examination does not exclude the possibility of colon polyps or colon cancer. Please consult the product user manual or refer to givenimaging.com for detailed information.



Bravo pH monitoring risk information

The risks of Bravo® pH monitoring include: premature detachment, discomfort, failure to detach, failure to attach, capsule aspiration, capsule retention, tears in the mucosa, bleeding and perforation. Endoscopic placement may present additional risks. Medical, endoscopic or surgical intervention may be necessary to address any of these complications, should they occur. Because the capsule contains a small magnet, patients should not have an MRI study within 30 days of undergoing the Bravo pH test. Please refer to the product user manual or givenimaging.com for detailed information.



Digitrapper pH-Z monitoring risk information

The risks of catheter insertion into the nasal passage associated with Digitrapper® pH- Z monitoring include discomfort, nasal pain, minor bleeding, runny nose, throat discomfort, irregular heartbeat with dizziness and perforation. In rare instances, the catheter may shift up or down causing false results, or the catheter may be misdirected into the trachea causing coughing or choking. Medical, endoscopic or surgical intervention may be necessary to address any of these complications, should they occur. The system is not compatible for use in an MRI magnetic field. Please refer to the product user manual or givenimaging.com for detailed information.



ManoScan ESO risk information

The risks of catheter insertion into the nasal passage associated with ManoScan® ESO high resolution manometry include discomfort, nasal pain, minor bleeding, runny nose, throat discomfort, irregular heartbeat with dizziness and perforation. In rare instances, the catheter may be misdirected into the trachea causing coughing or choking, or the catheter may shift up or down causing false results. Medical, endoscopic or surgical intervention may be necessary to address any of these complications, should they occur. The system is not compatible for use in an MRI magnetic field. Please refer to the product user manual or givenimaging.com for detailed information.



ManoScan AR risk information

Procedure complications are rare but may occur. The risks of ManoScan® AR high resolution manometry include perforation or bleeding of the intestinal wall. Patients with previous rectal surgery, bowel inflammation or bowel obstruction may have a higher risk for iatrogenic bowel perforation. Medical, endoscopic or surgical intervention may be necessary to address any of these complications, should they occur. The system is not compatible for use in an MRI magnetic field. Please refer to the product user manual or givenimaging.com for detailed information.


Combined ManoScan risk information

The risks of catheter insertion into the nasal passage associated with ManoScan® ESO high resolution manometry include discomfort, nasal pain, minor bleeding, runny nose, throat discomfort, irregular heartbeat with dizziness and perforation. In rare instances, the catheter may be misdirected into the trachea causing coughing or choking, or the catheter may shift up or down causing false results.

The risks of ManoScan® AR high resolution manometry include perforation or bleeding of the intestinal wall. Patients with previous rectal surgery, bowel inflammation or bowel obstruction may have a higher risk for iatrogenic bowel perforation.

Medical, endoscopic or surgical intervention may be necessary to address any of these complications, should they occur. These systems are not compatible for use in an MRI magnetic field. Please refer to the respective product user manual or givenimaging.com for detailed information.


SmartPill GI motility monitoring risk information

Before administering the SmartPill® motility capsule, rule out physiological and/or mechanical GI obstruction as a cause of patient symptoms. Significant data dropout can occur in severely obese patients (>40 BMI). Do not perform an MRI until capsule passage is confirmed by physician review of the MotiliGI® graph or an x-ray of the kidneys, ureter and bladder (KUB). If a SmartPill capsule is in the body during an MRI test, there is a risk of damage to the GI tract. The risks of SmartPill motility monitoring include capsule retention and aspiration. Please refer to the product user manual or givenimaging.com for detailed information.

Pudendal nerve latency testing (PNTML) risk information brochures, flyers, etc.: Adverse events may occur in patients with absent or reduced pain sensation, or in patients who are anesthetized or comatose. A risk may be possible to neonates and very young children or patients otherwise unable to communicate in the event of prolonged or high intensity stimulation. Medical advice should be sought to determine the risks of Pudendal Nerve Latency Testing in patients with implanted cardiac pacemakers or other implanted medical. The system is not compatible for use in an MRI magnetic field. Medical, endoscopic or surgical intervention may be necessary to address any complications, should they occur. Please refer to the product user manual.